Search Result

Results for "

thrombosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Amino Acid Derivatives (1) Apoptosis (6) Autophagy (3) Biochemical Assay Reagents (2) Calcium Channel (1) Caspase (3) Cathepsin (1) COX (4) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (1) Endogenous Metabolite (3) Factor VIIa (1) Factor Xa (12) Glycoprotein VI (1) HIF/HIF Prolyl-Hydroxylase (2) Integrin (6) Interleukin Related (1) Isotope-Labeled Compounds (2) Kallikrein (2) Mitophagy (3) MMP (1) Na+/K+ ATPase (1) NF-κB (4) NTPDase (3) P-selectin (1) P2X Receptor (1) P2Y Receptor (6) p38 MAPK (3) PAI-1 (2) Phospholipase (1) PI3K (1) Prostaglandin Receptor (5) Protease Activated Receptor (PAR) (4) Radionuclide-Drug Conjugates (RDCs) (2) SARS-CoV (1) SOD (1) Somatostatin Receptor (2) TAM Receptor (1) Thrombin (6) Virus Protease (3) VSV (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (79) Endocrinology (2) Infection (5) Inflammation/Immunology (12) Metabolic Disease (8) Neurological Disease (7)
Oligonucleotides:	Aptamers (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Morusinol	Others	Cardiovascular Disease
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo .

Cloricromen hydrochloride Cloricromene hydrochloride	Others	Cardiovascular Disease
Cloricromen (Cloricromene) hydrochloride is a platelet aggregation inhibitor. Cloricromen hydrochloride can inhibit platelet aggregation in man and in experimental thrombosis .

Flovagatran TGN 255	Thrombin	Cardiovascular Disease
Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis .

BMS-189664	Thrombin	Cardiovascular Disease
BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research .

FXIa-IN-13	Factor Xa	Cardiovascular Disease
FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .

Cloricromen Cloricromene; AD6	Biochemical Assay Reagents	Cardiovascular Disease
Cloricromen (Cloricromene) is a platelet aggregation inhibitor. Cloricromen can inhibit platelet aggregation in man and in experimental thrombosis .

FXIIa-IN-1	Others	Cardiovascular Disease
XIIa-IN-1-IN-3 (Compound 22) is a Factor XIIa inhibitor (K_i ^app: 97.8 nM). XIIa-IN-1-IN-3 can be used for research of thrombosis .

FXIIa-IN-2	Others	Cardiovascular Disease
FXIIa-IN-1-IN-2 (Compound 21) is a Factor XIIa inhibitor (K_i ^app: 62.2 nM). FXIIa-IN-1-IN-2 can be used for research of thrombosis .

Elinogrel potassium PRT060128 potassium	P2Y Receptor	Inflammation/Immunology
Elinogrel (PRT060128) potassium is a reversible, competitive and orally active P2Y₁₂ antagonist. Elinogrel potassium inhibits thrombosis .

BX 667	P2Y Receptor	Cardiovascular Disease
BX 667 is an orally active reversible P2Y(12) receptor antagonist. BX 667 attenuates thrombosis .

D-Pro-Phe-Arg-Chloromethylketone	Factor Xa Kallikrein	Cardiovascular Disease Neurological Disease
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation .

Hoe 892 S792892A	Others	Cardiovascular Disease
Hoe 892 (S792892A) is an orally active prostacyclin derivative with antiplatelet aggregation and vasodilatory activity. Hoe 892 can be used in the study of cardiovascular diseases such as thrombosis .

Thromboxane B1 TXB1	Prostaglandin Receptor	Cardiovascular Disease
Thromboxane B1 (TXB1) is one of thromboxane B (TXB) family members. Thromboxane is a member of the family of lipids known as eicosanoids. Thromboxane is named for its role in blood clot formation (thrombosis) .

L-739758	Integrin	Cardiovascular Disease
L-739758 is an antagonist for αIIbβ3 integrin (platelet glycoprotein IIb/IIIa). L-739758 acts as a peptidomimetic, binds to αIIbβ3 integrin by mimicking the interaction of the RGD (arginine-glycine-aspartic acid) motif, and is involved in the blood coagulation process. L-739758 inhibits platelet aggregation, and is used for thrombosis research .

12(S)-HETrE	Others	Cardiovascular Disease
12(S)-HETrE is a fatty acid metabolite that inhibits platelet aggregation. 12(S)-HETrE can be used in thrombosis-related research .

NTPDase-IN-3	NTPDase	Cardiovascular Disease Cancer
NTPDase-IN-3 (Compound 5e) is a NTPDase inhibitor, with IC₅₀ values of: 0.38 μM (NTPDase3), 0.05 μM (NTPDase8), 0.21 μM (NTPDase1), and 1.07 μM (NTPDase2). NTPDase-IN-3 can be used in the research of cancers and thrombosis .

Adenosine 5'-diphosphate disodium 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

h-NTPDase-IN-1	NTPDase	Cancer
h-NTPDase-IN-1 (Compound 3i) is a h-NTPDase inhibitor (IC₅₀: 2.88 μM and 0.72 μM for h-NTPDase1 and h-NTPDase3 respectively). h-NTPDase-IN-1 can be used for research of thrombosis, inflammation, diabetes, and cancer .

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

EA4	Phospholipase	Cardiovascular Disease
EA4, a derivative of quinone, is an inhibitor for both rPLA and cPLA. EA4 can inhibit rPLA₂ with a K_i value of 130 μM. EA4 can be used for the research of hemostasis, thrombosis, and erythropoiesis .

FXIIa-IN-5	Thrombin	Cardiovascular Disease
FXIIa-IN-5 (Compound 4J) is an orally active, selective inhibitor for factor XIIa (FXIIa), with IC₅₀ of 21 nM. FXIIa-IN-5 inhibits the intrinsic coagulation pathways, and exhibits anti-inflammatory and antithrombotic activity in Carrageenan (HY-125474)-induced mice thrombosis models. FXIIa-IN-5 exhibits moderate pharmacokinetic characteristics and slightly toxicity (at 100 mg/kg) .

FXIa-IN-9	Factor Xa	Cardiovascular Disease
FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa K_i: 0.17 nM, rabbit FXIa K_i: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .

NSC 405020 1 Publications Verification	MMP	Cardiovascular Disease Cancer
NSC 405020 is a specific MMP14 inhibitor. NSC 405020 can directly interact with the hemopexin domain of MMP14. NSC 405020 reduces the expression of full length and active cleaved Notch3 (NICD3). NSC 405020 can be used to research vestibular schwannoma, hemostasis and thrombosis .

UNC2881	VSV TAM Receptor	Cardiovascular Disease
UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC₅₀ value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC₅₀s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research .

Sarpogrelate hydrochloride 1 Publications Verification MCI-9042	5-HT Receptor	Cardiovascular Disease
Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT₂R antagonist, with pK_is of 8.52, 6.57, and 7.43 for 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT₁, 5-HT₃, 5-HT₄, α₁-, α₂- and β-adrenoreceptor, histamine H₁, H₂ and muscarinic M₃ receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis .

Ifetroban BMS-180291	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

Ifetroban sodium 1 Publications Verification BMS-180291 sodium	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

ONO-3307	Kallikrein	Cardiovascular Disease
ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases .

Aspirin Maximum Cited Publications 19 Publications Verification Acetylsalicylic Acid; ASA	COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .

Aspirin lithium Acetylsalicylic Acid lithium; ASA lithium	COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .

Collagen-IN-1	Others	Cardiovascular Disease
Collagen-IN-1 (compound 3), an ortho-carbonyl hydroquinone derivative, is a selective inhibitor on collagen. Collagen-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner with an IC₅₀ value of 1.77 μM. Collagen-IN-1 reduces the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelet. Collagen-IN-1 has the potential for platelet-related thrombosis diseases research .

LI-2242	Others	Neurological Disease Metabolic Disease
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .

AZD 9684	Others	Cardiovascular Disease
AZD 9684 is a carboxypeptidase U inhibitor,and can be used for study of thrombus .

Selatogrel ACT-246475	P2Y Receptor	Cardiovascular Disease
Selatogrel (ACT-246475) is a reversible and selective P2Y₁₂ receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy .

BT100 sodium	Integrin	Cardiovascular Disease
BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

BMS-593214	Factor VIIa	Cardiovascular Disease
BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT) .

Octimibate	Others	Cardiovascular Disease
Octimibate is a non-prostaglandin platelet aggregation inhibitor and cycloprostaglandin agonist. Octimibate can be used in the study of cardiovascular diseases (atherosclerosis and thrombosis) .

FaX-IN-1	Factor Xa	Cardiovascular Disease
FaX-IN-1 (compound 11A) is an intermediate in the preparation of FaX inhibitors and was used to study the inhibitory activity against venous thrombosis in rats .

BT200	Integrin	Cardiovascular Disease
BT200, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

BT200 sodium	Integrin	Cardiovascular Disease
BT200 sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

Breviscapine Breviscapinun	Others	Cardiovascular Disease
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

Desirudin CGP 39393; Revasc	Thrombin	Cardiovascular Disease
Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction .

BPTU BMS-646786	P2Y Receptor	Neurological Disease Cancer
BPTU (BMS-646786) is a non-nucleotide P2Y₁ receptor allosteric antagonist with antithrombotic activity. BPTU is able to block the P2Y1 receptor located at the neuromuscular junction of the gastrointestinal tract .

HMCEF	P-selectin	Cardiovascular Disease Inflammation/Immunology
HMCEF is an orally active P-selectin inhibitor and inhibits P-selectin expression. HMCEF blocks the interaction between P-selectin and natural ligands, such as PSGL-1. HMCEF inhibits thrombosis and inflammation in mice .

PAR4 antagonist 5	Protease Activated Receptor (PAR)	Cardiovascular Disease
PAR4 antagonist 5 (compound 1) is a PAR4 antagonist with an IC₅₀ less than 20 μM and potent anti-platelet aggregation activity. PAR4 antagonist 5 can be used for research of thrombosis disease .

ANO61	Calcium Channel	Cardiovascular Disease
ANO61 is a dibenzyl formamide derivative, which exhibits an antiplatelet efficacy through modulation of thrombin-induced Ca ²⁺ response with an IC₅₀ of 47.7 μM .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library

1,025 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,025 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

HY-L193

PBCRBS Traditional Chinese Medicine Compound Library

1,051 compounds

Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields.

MCE can supply 1,051 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.

Cat. No.	Product Name	Type

HY-D0199

Adenosine 5'-diphosphate disodium 1 Publications Verification	Biochemical Assay Reagents
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis .

HY-125864

Fibrinogen (Bovine)

Native Proteins

Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-NP021

Human D-dimer protein D Dimer protein; D Dimer antigen; Human D-dimer protein	Native Proteins
Human D-dimer protein is a good surrogate biomarker of thrombosis. Human D-dimer protein is the end product of fibrinolysis .

HY-120978

Omega-3 arachidonic acid methyl ester

ω-3 Arachidonic acid methyl ester; (all-Z)-8,11,14,17-Eicosatetraenoic acid methyl ester

Drug Delivery

omega-3 Arachidonic Acid methyl ester, mainly docosahexaenoic acid, eicosapentaenoic acid and α-Linoleic acid, represented by linoleic acid, is an essential dietary nutrient required for normal growth and development.Omega-3Methyl arachidonic acid is a rare fatty acid Omega-3Neutral fat-soluble form of arachidonic acid. Omega-3Fatty acids, as a group, were associated with reduced inflammation and autoimmune activity, as well as reduced thrombosis and platelet activation.

Cat. No.	Product Name	Target	Research Area

HY-P4245

D-Pro-Phe-Arg-Chloromethylketone	Factor Xa Kallikrein	Cardiovascular Disease Neurological Disease
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation .

HY-P5126

DOTA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis .

HY-P5126A

DOTA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis .

HY-P10014

Bibapcitide	Peptides	Cardiovascular Disease
Bibapcitide, a 26 amino acid, inhibits thrombosis .

HY-P10577

RAG8 peptide	Protease Activated Receptor (PAR)	Cardiovascular Disease
RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research .

HY-P1711

L 366763	Peptides	Cardiovascular Disease
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .

HY-P3012

Cathepsin G	Cathepsin	Inflammation/Immunology
Cathepsin G acts as a potent agonist of human platelet activation leading to their aggregation., and can be used for screening of relevant inhibitors .

Cat. No.	Product Name	Target	Research Area

HY-P99794

Osocimab BAY 1213790	Factor Xa	Cardiovascular Disease
Osocimab (BAY 1213790), an anti-FXIa antibody (K_i=2.4 nM; EC₅₀=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .

Cat. No.	Product Name	Chemical Structure

HY-10564S

Sarpogrelate-d3 hydrochloride

Sarpogrelate-d₃ (hydrochloride) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis[1][2][3].

HY-113420S2

11-Dehydro-thromboxane B2-13C5
11-Dehydro-thromboxane B2- ¹³C₅ is ¹³C labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

Cat. No.	Product Name		Classification

HY-153999A

BT200 sodium		Aptamers
BT200 sodium, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153998

BT100 sodium		Aptamers
BT100 (sodium), a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-153999

BT200		Aptamers
BT200, a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-156501

BT101 sodium		Aptamers
BT101 (sodium), a complementary aptamer, has been developed to specifically inhibit BT100 function. BT100, a aptamer, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis .

HY-160067

T18.3 aptamer sodium		Aptamers
T18.3 aptamer sodium is an anticoagulant RNA aptamer targeting FV/Va and eliminates the interaction of FV/FVa with phospholipid membranes. T18.3 aptamer sodium exhibits clinically relevant anticoagulant activity in plasma and whole blood and acts synergistically with low molecular weight heparin. The anticoagulant activity of T18.3 aptamer sodium is effectively and rapidly reversed by protamine sulfate .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks